The Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Nalls, Michael A
Singleton, Andrew B
Bras, Jose M
MetadataShow full item record
CitationJ. Neurol. Neurosurg. Psychiatr. 2013, 84 (6):666-73
AbstractThe catechol-O-methyltranferase (COMT) is one of the main enzymes that metabolise dopamine in the brain. The Val158Met polymorphism in the COMT gene (rs4680) causes a trimodal distribution of high (Val/Val), intermediate (Val/Met) and low (Met/Met) enzyme activity. We tested whether the Val158Met polymorphism is a modifier of the age at onset (AAO) in Parkinson's disease (PD). The rs4680 was genotyped in a total of 16 609 subjects from five independent cohorts of European and North American origin (5886 patients with PD and 10 723 healthy controls). The multivariate analysis for comparing PD and control groups was based on a stepwise logistic regression, with gender, age and cohort origin included in the initial model. The multivariate analysis of the AAO was a mixed linear model, with COMT genotype and gender considered as fixed effects and cohort and cohort-gender interaction as random effects. COMT genotype was coded as a quantitative variable, assuming a codominant genetic effect. The distribution of the COMT polymorphism was not significantly different in patients and controls (p=0.22). The Val allele had a significant effect on the AAO with a younger AAO in patients with the Val/Val (57.1±13.9, p=0.03) than the Val/Met (57.4±13.9) and the Met/Met genotypes (58.3±13.5). The difference was greater in men (1.9 years between Val/Val and Met/Met, p=0.007) than in women (0.2 years, p=0.81). Thus, the Val158Met COMT polymorphism is not associated with PD in the Caucasian population but acts as a modifier of the AAO in PD with a sexual dimorphism: the Val allele is associated with a younger AAO in men with idiopathic PD.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.
RightsArchived with thanks to Journal of neurology, neurosurgery, and psychiatry
- Dopaminergic denervation severity depends on COMT Val158Met polymorphism in Parkinson's disease.
- Authors: Muellner J, Gharrad I, Habert MO, Kas A, Martini JB, Cormier-Dequaire F, Tahiri K, Vidailhet M, Meier N, Brice A, Schuepbach M, Mallet A, Hartmann A, Corvol JC
- Issue date: 2015 May
- Catechol-O-methyltransferase Val158Met polymorphism influences prefrontal executive function in early Parkinson's disease.
- Authors: Zhang Y, Feng S, Nie K, Zhao X, Gan R, Wang L, Zhao J, Tang H, Gao L, Zhu R, Wang L, Zhang Y
- Issue date: 2016 Oct 15
- Associations of catechol-O-methyltransferase (rs4680) single nucleotide polymorphisms with opioid use and dose among adults with chronic pain.
- Authors: Hooten WM, Biernacka JM, OʼBrien TG, Cunningham JM, Black JL
- Issue date: 2019 Jan
- Catechol-O-methyltransferase Val158Met polymorphism: modulation of wearing-off susceptibility in a Chinese cohort of Parkinson's disease.
- Authors: Wu H, Dong F, Wang Y, Xiao Q, Yang Q, Zhao J, Quinn TJ, Chen SD, Liu J
- Issue date: 2014 Oct
- Effect of catechol-O-methyltransferase (rs4680) single-nucleotide polymorphism on opioid-induced hyperalgesia in adults with chronic pain.
- Authors: Hooten WM, Hu D, Cunningham JM, Black JL 3rd
- Issue date: 2019 Jan-Dec